Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast cancer (TNBC). Globally, breast cancer is the most common malignancy in women and the second most common cancer overall. The term TNBC is used to define tumours that do not express oestrogen receptors, progesterone receptors and HER2 receptors. TNBC comprises 10 -15% of all breast cancers. It remains the subtype with poorest outcome and there is a significant need to develop new therapies for this group of patients especially. Moreover, the PDL1-negative tumour has demonstrated no benefit from standard 1st line treatment of chemotherapy plus immune checkpoint inhibitors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku co najmniej 18 lat
- •Chętna i zdolna do podpisania świadomej zgody
- •Zdolna do przestrzegania protokołu badania
- •Rak potrójnie ujemny (brak receptorów hormonalnych i HER2)
- •Ujemna dla PD-L1 (wynik testu poniżej 10)
- •Co najmniej jeden widoczny guz o wymiarach ≥10 mm (chyba że węzeł chłonny ≥15 mm) potwierdzony tomografią lub rezonansem w ciągu 28 dni
- •Dostęp do próbki guza do badania genetycznego lub możliwość pobrania biopsji
- •Ogólny stan zdrowia 0-1 (według skali ECOG) i spodziewana długość życia ≥12 tygodni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- May 22, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (2)
Barts Cancer Institute, Centre of Experimental Cancer Medicine
London, United Kingdom
Barts Health NHS Trust
London, United Kingdom
Trial contact
Peter Schmid, MD PhD, FRCP
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.